Biomedical Polymer Insights: Role-Based Task Map, Six Key Material Levers, and a Risk-Driven Evidence Chain (including the Product Navigation Guide and Product Tables 1–3)
Biomedical Polymer Insights: Role-Based Task Map, Six Key Material Levers, and a Risk-Driven Evidence Chain (including the Product Navigation Guide and Product Tables 1–3)
I. Background
1.1 Common Applications
Many medical products can feel comfortable, conform well, be implantable, or enable controlled drug release because polymers are “quietly doing the work” behind the scenes:
1. Soft contact lenses: Silicone hydrogels have become one of the mainstream material systems. A key advantage is high oxygen transmissibility (Dk/t). However, wearing comfort still depends strongly on surface wettability/hydrophilic modification, material modulus, deposition and lens-care systems, and other factors (oxygen transmissibility is necessary, but not the only determinant).
2. Drug delivery: Polymeric nanoparticles/microparticles are often used to “package” therapeutic molecules, providing protection and stability in vivo. Through surface engineering, they can address delivery barriers and influence cellular uptake and biodistribution.
3. Controlled-release implants and tissue repair: Biodegradable polymers such as PLGA (poly(lactic-co-glycolic acid)) can be processed into many structural forms. Their degradation and release behaviors can be systematically tuned and verified, which is why they have been repeatedly adopted and iterated over long periods.
1.2 The Core Challenge
Biomedical polymers are often not difficult to “make” or “use.” The hard part is whether they can work long-term in complex biological environments in a stable, predictable, and controllable way.
1. Why it becomes difficult (dynamic biointerfaces): Once a material contacts body fluids/blood, protein adsorption occurs. In plasma/blood, adsorbed proteins undergo time-dependent competition and exchange (the Vroman effect is a classic example), meaning surface properties evolve over time.
2. Typical consequences in implant/tissue-contact scenarios: foreign body reaction (FBR): Under implantation conditions, this “biologically redefined surface” can trigger inflammatory and healing cascades, often progressing toward FBR (foreign body reaction/response). This is associated with macrophages, foreign body giant cells, and fibrotic encapsulation, which then affect long-term function and failure modes.
3. Typical consequences in blood-contact scenarios: hemocompatibility issues: For blood-contacting materials, evaluation often focuses more on hemocompatibility, including the coagulation cascade, platelet responses, and complement activation. Protein adsorption is frequently one of the important initiating events for these processes.
1.3 “Same Material, Different Use—Different Standards”
When the same polymer is used in different scenarios (blood contact/subcutaneous implantation/ocular surface/bone repair), the success criteria change with anatomical contact site and contact duration. It is not enough to “meet performance specs”—you must also control the biological risks and failure modes specific to that scenario.
II. Fundamental Concepts and an Evaluation Framework
2.1 What is a polymer?
a) Polymer: A polymer is a substance composed of macromolecules.
b) Macromolecule (also called a polymer molecule): A macromolecule is a molecule of high relative molecular mass, whose structure essentially contains repeated low-molecular-weight units.
Key takeaways:
c) Polymers inherently provide tunable engineering degrees of freedom—for example, molecular weight and distribution, chain architecture/branching, repeat units and functional groups, and network/crosslinking structures.
2.2 What is a biomaterial?
a) Biomaterial: Biomaterials can be natural or synthetic, used in medical applications to support, enhance, or replace tissues or biological functions.
b) What are “biomedical polymers”? Biomaterial systems in which polymers are the primary component—i.e., a materials platform serving medical tasks such as delivery, repair/scaffolding, adhesion and sealing, surface coatings and device functionalization, and diagnostic/theranostic devices, among others.
2.3 Why must “risk management” be introduced?
a) Biocompatibility is not a fixed label on a material: Once a material enters body fluids/blood, its surface is rapidly “rewritten” by proteins and other components, and subsequent cellular and immune responses change accordingly.
b) Same material, different use → completely different risks and evidence: Changing the contact site (blood/subcutaneous/ocular surface, etc.), contact time (short-term/long-term), or whether it is implanted changes what risks matter and what evidence is required.
c) Therefore, evaluation must be organized as “use scenario → risk → evidence”: The core logic of ISO 10993-1 and FDA guidance is to use risk assessment to decide which tests and controls are needed. The goal is not to prove “the material is good,” but whether it is acceptable in that specific scenario.
III. Role Map: How to Classify Biomedical Polymers by “Task”
Role / Task | Common Forms | Key Levers / Common Risks | Representative Material Families |
A. Drug delivery & controlled release (bringing drugs to the right place, retaining them, releasing them on schedule) | Polymeric nanoparticles/microparticles; implant depots | Levers: stability + biodistribution + release mechanism. Risks: initial burst release / loss of release control; behavior changes after “biological conditioning” of the surface | PLGA is widely used in controlled-release and delivery systems; “polymeric nanoparticles” protect drugs and facilitate delivery |
B. Tissue engineering & regenerative scaffolds (helping cells “live in” and “grow well”) | Hydrogel scaffolds; porous scaffolds/fibers/3D-printed structures | Levers: mechanical matching + pore/network architecture + cell interactions. Risks: mechanics/degradation not synchronized with tissue repair; poor integration | Natural hydrogels such as HA (hyaluronic acid), alginate, gelatin, and more controllable synthetic network hydrogels are common scaffold routes |
C. Wound repair / hemostasis / sealing / medical adhesion (sticking and sealing on wet tissue) | Surgical sealants; hemostatic materials; in situ gelling hydrogels | Levers: wet adhesion + gelation kinetics + wash-off resistance. Risks: adhesion decay in aqueous environments; swelling/irritation and local inflammation | Common approaches include in situ gelling/injectable hydrogel-type tissue adhesives (requirements vary greatly by surgical scenario) |
D. Medical device surface coatings (anti-fouling / antimicrobial / hemocompatible) | Surface grafting/brush layers; anti-fouling coatings; hemocompatible coatings | Levers: first suppress protein adsorption → then disrupt platelet/bacterial adhesion cascades. Risks: coating delamination/aging leading to performance drift | PEG (poly(ethylene glycol)) and zwitterionic polymers are classic anti-protein-adsorption/anti-fouling routes, often used to reduce protein adsorption and platelet adhesion |
E. Diagnostic/sensing/imaging carriers (making signals readable and locatable) | Hydrogel sensing interfaces; functionalized polymer layers; nanoparticle carriers for imaging agents | Levers: signal stability + anti-fouling + reliable immobilization. Risks: biofluid contamination-induced drift; probe/component leakage | Polymeric nanocarriers/functionalized interfaces improve stability and signal usability (materials vary; selection depends on readout modality) |
F. Resorbable or long-term implant device bodies (the material itself is the device) | Resorbable sutures, fixation parts, support structures; or long-term stable elastomeric devices | Levers: strength retention + fatigue reliability + (if degradable) degradation tempo. Risks: strength decay in body fluids; fibrotic encapsulation after implantation affecting function | PLA (polylactic acid)/PLGA/PCL (polycaprolactone) are used across many medical applications; implantation may trigger FBR (foreign body response) and fibrotic encapsulation, impacting long-term performance |
Additional note for Role D: Anti-fouling layers can often reduce protein adsorption—an upstream “starting point.” However, hemocompatibility still must be evaluated and validated systematically against blood-contact endpoints (coagulation, platelets, complement, etc.), with appropriate controls.
IV. Six Material Knobs: From Structure to Biointerfaces and Failure Modes
After defining the “task role,” what truly determines success or failure is: which material knobs you tuned, and how those knobs reshape the dynamic interface after entering body fluids/blood (protein adsorption and exchange) and the subsequent immune/repair responses.
Time-dependent competitive adsorption and exchange of protein layers (often referred to as the Vroman effect) is one classic mechanism illustrating that “the interface will be rewritten.” Common post-implantation foreign body response/reaction (FBR) is also tightly coupled to the chemical and physical characteristics of material surfaces, influencing long-term outcomes such as fibrotic encapsulation.
4.1 Table of the Six Material Knobs
Knob (Tunable Variable) | Impact Chain (Structure → Interface/Behavior) | Most Sensitive Roles (A–F) | Common Phenomena / How to Tune |
1. Hydrophilic–hydrophobic balance (surface energy, wettability) | Determines the strength and conformation of protein adsorption and the tendency for cell/platelet adhesion → the starting point of “interface rewriting” | D coatings; F implants; E sensors; A delivery | Phenomena: anti-fouling decay, increased thrombosis/adhesion, signal drift in biofluids. Tuning: increase hydrophilic/anti-fouling components; optimize surface-layer stability and density (avoid “coating drift”). |
2. Surface charge / functional groups (cationic/anionic/zwitterionic) | Influences interactions with proteins/cell membranes/nucleic acids, complement/inflammation risk, and cellular uptake | A delivery; D coatings; E sensors | Phenomena: increased cytotoxicity, enhanced nonspecific adsorption, abnormal biodistribution. Tuning: confine “strong interactions” to scenarios where they are needed (e.g., uptake); in other scenarios, prioritize reducing nonspecific interactions. |
3. Molecular weight & distribution (Mw / PDI) | Affects viscosity/mechanics, diffusion and clearance rates, chain entanglement, and processing window | A delivery; B scaffolds; F device bodies | Phenomena: large batch-to-batch variability, drifting release profiles, unstable mechanics and molding/forming. Tuning: lock in the Mw window and distribution; use the same method (GPC/SEC, etc.) for consistency control. |
4. Chain architecture & crystallinity/Tg (flexibility/rigidity, crystalline/amorphous) | Governs strength retention, fatigue, hydration-induced mechanical changes, and long-term stability | F device bodies; B scaffolds; C sealing | Phenomena: embrittlement/softening in body fluids, fatigue cracking, poor shape retention. Tuning: via copolymerization/plasticization/crystallinity control so that “post-hydration mechanics” still fall within the target tissue window. |
5. Network structure & crosslink density (hydrogels/in situ gelation) | Determines swelling, diffusion/release, cell migration, and sealing strength (the physics behind “mesh size”) | B scaffolds; C sealing/hemostasis; A depots | Phenomena: excessive swelling, release too fast/too slow, cells cannot infiltrate or strength is insufficient. Tuning: balance “strength–diffusion–biology” using crosslink density, dynamic/reversible crosslinks, and curing/gelation rate. |
6. Degradation mechanism & products (hydrolytic/enzymatic/oxidative) | Sets lifetime window, local microenvironment (e.g., acidification), and risks of inflammation/fibrosis | A delivery; B scaffolds; F device bodies | Phenomena: late-stage inflammation/encapsulation, loss of release control in later phases, cliff-like strength drop. Tuning: define a scenario-matched time axis for “strength retention/release/resorption,” and track degradation products and local responses. Long-term implantation outcomes are closely tied to FBR/fibrosis. |
V. Evaluation by Contact Scenario: From “How It’s Used” to “How It’s Proven”
5.1 Define the “Contact Scenario”
Biocompatibility is not a slogan. It means that, in a specific use scenario, the relevant biological risks of a material are within an acceptable range and do not hinder the intended function. Therefore, all subsequent decisions—which tests to run, which endpoints to evaluate, and what controls to use—should be derived from the use scenario first.
Contact scenario includes:
1. Where it contacts: skin / mucosa / tissue / bone / blood, etc.
2. How long it contacts: limited (≤24 h) / prolonged (>24 h and ≤30 d) / long-term (>30 d)
3. How it contacts: surface contact or implantation? blood contact? degradable/resorbable? possible release of extractables/migrating components (when necessary, also consider that sterilization methods may alter the material and the extractables profile)
4. Note: This duration classification and the selection of corresponding biological endpoints are typically organized under the risk management framework of ISO 10993-1 and the endpoint tables used in FDA guidance.
Intuitive takeaway: Even for the same “polymer,” once the contact site, duration, or contact mode changes, the risk points that must be addressed and the evidence package must change accordingly.
5.2 What Is the Minimum You Must Prove: Organize Evidence Around Key Risks
The goal of a “minimum closed loop” is to center on the key risks of the scenario and answer two questions in a closed loop:
1. Can it be used safely? (risk is acceptable)
2. Can it accomplish the task? (functionality for the intended use is verifiable and reproducible—note that “effective” here means functionally effective, not clinical drug efficacy)
It is recommended to organize evidence in the sequence of “chemistry & structure → function/performance → biological effects.”
1. Chemistry/structure layer: what exactly was made
Describe composition, key structural parameters, and potential sources of impurities; identify extractables/leachables (E/L) and related risk signals—this layer answers “where risks come from” and “why batches may vary.”
2. Function/performance layer: can it work in this task
Demonstrate “it works and is reproducible” using task-relevant metrics:
a) Delivery/controlled release: release profile and stability; burst-release risk
b) Scaffolds: mechanical window; pore/network architecture and performance after hydration
c) Coatings: anti-fouling performance/durability; drift after aging
d) Sealing/hemostasis: wet adhesion, gelation window, swelling control, etc.
3. Biological effects layer: is risk controllable in this contact scenario (choose based on risk assessment and contact scenario)
a) Cytotoxicity (ISO 10993-5), irritation (ISO 10993-23), skin sensitization (ISO 10993-10)
b) Blood contact: focus on hemocompatibility endpoints (ISO 10993-4)
c) Implantation/long-term contact: focus on local tissue response/tissue compatibility and tissue reactions linked to long-term failure (ISO 10993-6)
d) Note: In the updated system, irritation testing has been separated from ISO 10993-10 into ISO 10993-23; ISO 10993-10 now primarily covers sensitization.
Control principles:
a) At each layer, it is recommended to set up key controls (benchmark controls + design-variable controls). Otherwise, “good-looking” data are difficult to prove as coming from material design rather than process fluctuation or chance factors.
VI. Product Navigation Table | Medical Polymers: Locate Tables 1–3 by “Research Task / Experimental Scenario”
Need / Scenario (Typical Research/Experimental Task) | Which Table to Check First | Why This Table First | Representative Products in the Table |
Hydrogels/dressings/hemostasis: want a base material that “can gel, retain water, and encapsulate cells/drugs” (mainly ionic crosslinking/physical gels) | Table 1 | Natural/Bio-based Materials & Cell Interfaces | Natural polysaccharides/proteins are more likely to offer biocompatibility and ECM-mimicking features; ionic crosslinking (alginate), viscoelasticity (HA), and protein gels (gelatin/collagen) align well with tissue-oriented application paths |
Cell culture adhesion/surface modification: want to improve adhesion on glass/plastic/hydrogel surfaces and reduce floating cells | Table 1 | Natural/Bio-based Materials & Cell Interfaces | For cell interfaces, prioritize “charged/ECM-signal” materials; coatings/pretreatments are more direct than changing the bulk substrate |
Drug delivery/sustained-release microspheres/resorbable scaffolds: need a polyester backbone that is “degradable, enables controlled release, and can form microspheres/nanoparticles/scaffolds” | Table 2 | Resorbable/Biodegradable Polymers | Degradation and release are largely determined by polyester family parameters (PLGA/PLA/PGA/PCL): composition, end groups, and molecular weight; choose “degradation rate and mechanical window” first, then process |
PEG hydrogels (photocuring/free-radical crosslinking): want controllable porosity/modulus for 3D encapsulation or microfluidic gels | Table 2 | Resorbable/Biodegradable Polymers | Key is “crosslinkable precursors and crosslink density”; PEGDA is the most common starting material |
Device structural parts/engineering plastics controls: need heat/chemical resistance and stable mechanics (injection molding/machining) for parts or reference materials | Table 3 | Non-degradable Synthetics & Device/Formulation Systems | Structural-part selection centers on mechanics/processing/sterilization compatibility; engineering plastics are concentrated in Table 3 |
Membrane separation/dialysis/filtration membrane research: care about film formation, pore structure, flux/selectivity, and protein adsorption | Table 3 | Non-degradable Synthetics & Device/Formulation Systems (also revisit cellulose systems in Table 1) | Engineering membranes commonly use polysulfone/cellulose acetate, etc.; different systems correspond to different solvents and phase-inversion windows |
Solubilization/stabilization/thermosensitive gel formulations (proteins/hydrophobic small molecules/local delivery): want mild, compatible, formulation-friendly systems | Table 3 | Non-degradable Synthetics & Device/Formulation Systems (some materials also in Table 1) | For formulation problems, first look for “surfactants/solubilizing polymers/hydrophilic segments” |
Gene/nucleic acid delivery (transfection, non-LNP options, layer-by-layer self-assembly): need cationic polymers | Table 3 | Non-degradable Synthetics & Device/Formulation Systems | Core is “cationic density / molecular weight / toxicity window”; Table 3 concentrates key materials |
Low-friction/wear-resistant/lubricious coatings or additives: catheters/seals/sliding parts and friction evaluation | Table 3 | Non-degradable Synthetics & Device/Formulation Systems | For interface problems, prioritize materials like “fluoropolymer micropowders/silicone oils” |
Tissue adhesion/rapid sealing: need instant curing and wet-surface compatibility | Table 3 | Non-degradable Synthetics & Device/Formulation Systems | Cyanoacrylates are the canonical scaffold; chain length affects flexibility and handling window |
Processing rheology/incoming QC/process consistency: need standards or processing-parameter controls | Table 3 | Non-degradable Synthetics & Device/Formulation Systems | In process development, establish measurable and reproducible metrics first |
Table 1 | Natural/Bio-based Materials and Cell Interfaces (Polysaccharides/Proteins/ECM/GAG)
Category | CAS No. | Aladdin Cat. No. | Name | Specification / Purity | Selection Notes & Typical Applications |
Natural polysaccharide / ionic-crosslinked hydrogel | 9005-38-3 | Sodium alginate (from brown algae) | Medium viscosity | A classic Ca²⁺ ionic-crosslinking hydrogel base; used for wound dressings/hemostatic sponges, cell/drug encapsulation and microspheres (dropwise gelation), 3D bioprinting bio-inks and thickening systems. Key selection factors: viscosity window, G/M ratio, gel strength, and sterility/endotoxin requirements. | |
Cellulose derivative / pharm excipient & gel | 9004-32-4 | Sodium carboxymethylcellulose (CMC) | Viscosity: 1000–1400 mPa·s, USP grade | High-viscosity thickening, suspension stabilization, and film formation; common in ophthalmic lubrication, gel matrices, controlled release, and viscoelastic tuning in biomaterials. USP grade supports compliance/impurity control. Selection: viscosity, DS/salt content, and shear-thinning behavior. | |
Natural polysaccharide / modifiable hydrogel | 9004-54-0 | Dextran | Premium grade | Hydrophilic polysaccharide for hydrogels/microspheres and surface modification (e.g., dextran chemical modification; anti-protein-adsorption coating concepts). Also used as a stabilizer for biomacromolecules/nanosystems. Selection: molecular weight and substitution/modification space. | |
Cellulose derivative / membrane material | 9004-35-7 | Cellulose acetate | Acetyl 39.8 wt%, hydroxyl 3.5 wt% | Classic membrane material (dialysis/filtration/sustained-release membranes, microporous membranes, coatings). Acetyl/hydroxyl content determines hydrophilicity, solubility, and flux/selectivity. Selection: degree of substitution, film-forming solvent system, and controllability of pore structure. | |
Cellulose derivative / controlled-release & film former | 9004-65-3 | Hydroxypropyl methylcellulose (HPMC) | Substitution type 2910; viscosity 400 mPa·s; methoxy 28–30%; hydroxypropyl 7.0–12% | A typical controlled-release matrix polymer and coating film former; forms a gel layer to control diffusion/erosion. 2910 substitution affects hydrophilicity and gel strength. Selection: viscosity grade, substitution type, swelling behavior, and release profile. | |
Natural protein / pharm gelatin | 9000-70-8 | Gelatin | PharmPure™, USP, BP, Ph.Eur; gel strength ~240 g Bloom | Classic protein gelling material; used in hemostatic materials, pharmaceutical capsules/coatings, tissue-engineering hydrogels/microspheres, and stabilizers (e.g., lyoprotectants). Bloom value correlates with gel strength and gelation behavior. Selection: Bloom, ash/endotoxin levels, and batch consistency. | |
GAG / viscoelasticity & lubrication (salt) | 9067-32-7 | Sodium hyaluronate | Medical grade | High water retention and viscoelasticity; used as viscoelastic reference in intra-articular studies, ophthalmic viscoelastic media, wound dressings/gels, and cell microenvironment materials. Salt form dissolves more readily and is more stable in preparation. Selection: molecular weight, viscoelastic profile, endotoxin. | |
GAG / viscoelasticity & lubrication (acid) | 9004-61-9 | Hyaluronic acid | Moligand™, from rooster comb | HA (non-sodium salt) suitable as a precursor/control for salt formation and crosslinking modification; used for viscoelastic tuning, water-retentive gels, and cell microenvironment materials. Key selection: molecular weight, purity, endotoxin/protein residues. | |
Natural protein / ECM structural protein | 9007-34-5 | Porcine collagen type I (Col I) | Moligand™, R&D grade | Core material for ECM mimicking in tissue engineering; used in scaffolds/coatings/hydrogels (with crosslinking systems) to promote cell adhesion and differentiation. Selection: source, purity/endotoxin, dissolution form (acid-soluble/enzyme-soluble), batch consistency. | |
Biomaterials support / cell-adhesion coating | 25988-63-0 | Poly-L-lysine hydrobromide | Mw 30–70 kDa | Positively charged surface modifier to enhance cell adhesion (coating on glass/plastic/hydrogel). Also used in layer-by-layer assembly and antibody/nucleic acid adsorption. Selection: molecular weight, coating concentration, and cell-type sensitivity. |
Table 2 | Resorbable/Biodegradable Polymers (Aliphatic Polyesters + PEG Crosslinking Precursors)
Category | CAS No. | Aladdin Cat. No. | Name | Specification / Purity | Selection Notes & Typical Applications |
Biodegradable aliphatic polyester | 26780-50-7 | Resomer® RG 505, poly(D,L-lactide-co-glycolide) (PLGA) | Ester-terminated, Mw 54,000–69,000 | Classic degradable carrier (microspheres/nanoparticles/sustained-release implants, tissue-engineering scaffolds). 50:50 typically degrades faster; ester-terminated often slower than acid-terminated and may help reduce early acidification. Selection: LA:GA ratio, end group, Mw/dispersity, solvent system. | |
Biodegradable aliphatic polyester | 24980-41-4 | Resomer® C 209, poly(ε-caprolactone) (PCL) | Ester-terminated | Slower degradation and better flexibility; suitable for long-term scaffolds/sustained release; processable into fibers/films. Often blended with PLA/PLGA to tune mechanics and degradation. Selection: molecular weight, crystallinity, processing temperature window. | |
Biodegradable aliphatic polyester | 26124-68-5 | Polyglycolide (PGA) | Intrinsic viscosity 1.4 dL/g | PGA: highly crystalline, relatively fast hydrolytic degradation; common for resorbable sutures, meshes, and scaffold references. Intrinsic viscosity correlates with molecular weight and strength retention. Selection: molecular weight, crystallinity, degradation/strength-retention curves. | |
Biodegradable aliphatic polyester | 26100-51-6 | Polylactic acid (PLA) | Mw ~60,000 | Widely used for degradable scaffolds/fixation devices/3D printing and sustained-release carriers. Generally slower degradation than PGA. Mw affects mechanics and degradation rate. Selection: D/L stereochemistry (crystallinity), Mw, processing temperature window. | |
Hydrophilic crosslinkable monomer / PEG hydrogel | 26570-48-9 | Poly(ethylene glycol) diacrylate (PEGDA) | Average Mw ~200, stabilized with MEHQ | Typical photo/free-radical crosslinking precursor for rapid PEG hydrogel construction (cell encapsulation, tissue engineering, microfluidic gels, release systems). Mn~200 yields high crosslink density, stiffer and denser gels. MEHQ is a polymerization inhibitor; formulation must consider its removal/impact. |
Table 3 | Non-degradable Synthetic Materials and Device/Formulation Systems (Engineering Plastics/Hydrophilic Functional Polymers/Interface Materials/Standards/Adhesives)
Category | CAS No. | Aladdin Cat. No. | Name | Specification / Purity | Selection Notes & Typical Applications |
Medical engineering plastic / general thermoplastic | 9002-88-4 | Polyethylene (PE) | Medium density | Inert, chemically resistant, easy to process; common in disposables/containers, liners/films, housings. For high-load implants, UHMWPE is often used as a reference. Selection: density/crystallinity, sterilization compatibility, extractables. | |
Medical engineering plastic / implant-grade structural material | 29658-26-2 | PEEK | 30% carbon-fiber reinforced | High strength/modulus, fatigue and chemical resistance, and relatively low imaging artifacts vs metals; common in orthopedic/spinal implants and device structural-part studies and wear/mechanics references. 30% CF reinforcement brings modulus closer to cortical bone. Selection: fiber content, processing, surface modification/coatings. | |
Hydrophilic synthetic polymer / film-forming & hydrogel base | 9002-89-5 | Mowiol® PVA-124 (poly(vinyl alcohol), PVA) | Viscosity 54–66 mPa·s | Good film-forming; hydrophilic and crosslinkable into hydrogels; used in hydrogel scaffolds, particle/encapsulation systems, bonding/coatings, and thickening. Selection: degree of hydrolysis and molecular weight (affects dissolution temperature, crystallinity, mechanics). | |
Hydrophilic synthetic polymer / thickening-lubrication-hydrogel | 25322-68-3 | Poly(ethylene oxide) | Viscosity 65–115 cps | Water-soluble polymer (same family as PEG); used as a lubricious additive for low-friction coatings, rheology modifier, hydrogel component, and release matrix. Selection: molecular weight (reflected by viscosity), swelling, shear sensitivity. | |
Hydrophilic synthetic polymer / solubilizer-stabilizer | 9003-39-8 | Polyvinylpyrrolidone (PVP) | For plant cell culture; average Mw 10,000 | Classic solubilizing/dispersing stabilizer; used in solid dispersions, nanoparticle stabilization, hydrophilic coatings, and hydrogel blends. 10k is lower Mw with less viscosity burden. Selection: K value/Mw and extractables. | |
Pharm excipient / surfactant-thermosensitive gel | 9003-11-6 | K434429 | Kolliphor® P 407 | EO 71.5–74.9% | Poloxamer 407: nonionic surfactant + thermogelling system (micellization/gelation upon warming). Used for poorly soluble drug solubilization, injectable/nasal/topical thermogels, and mild protein/cell formulations. Selection: EO/PO ratio and gel point. |
PEG derivative / hydrophilic modification-formulation aid | 9004-74-4 | Methoxy PEG 750 (mPEG 750) | Average Mw 750 | mPEG: used for hydrophilic modification/PEGylation concepts, plasticization/wetting, and pore-structure tuning (as porogen/solvent-phase modifier). Selection: molecular weight and whether end-group activation is required (this product is methoxy-terminated, suited to “capped hydrophilic chain” uses). | |
Cationic polymer / nucleic acid delivery & coatings | 9002-98-6 | Branched polyethylenimine (PEI) | Mw ~25,000 (LS), Mn ~10,000 (GPC), branched | Classic cationic polymer for gene/siRNA delivery and layer-by-layer coatings; branched PEI has strong buffering capacity but higher cytotoxicity risk. Selection: molecular weight, branching, N/P window, and cytocompatibility evaluation. | |
Hydrophilic methacrylate / hydrogel base | 25249-16-5 | Poly(2-hydroxyethyl methacrylate) | Average Mv 300,000, crystalline | Typical pHEMA-family hydrogel material; used for contact-lens/hydrophilic networks, sustained release, and biocompatible surfaces. Molecular weight affects film formation and mechanics; commonly used with crosslinkers to form stable hydrogels. | |
Silicone-based material / lubrication & interface control | 63148-62-9 | Silicone oil | 5 cSt (25°C) | Low-viscosity PDMS fluid; used for device lubrication, demolding/antifoaming, friction and surface-wetting studies (e.g., catheters/pump systems). Selection: viscosity, volatility/migration, compatibility with other materials. | |
Medical engineering plastic / transparent rigid material | 9011-14-7 | PMMA (poly(methyl methacrylate)) | General injection grade | Transparent, rigid, suitable for precision injection molding; used for device windows, disposable parts, dental/orthopedic resin references. Selection: residual monomer, crack resistance, sterilization method. | |
Medical engineering plastic / impact-resistant transparent parts | 25037-45-0 | Polycarbonate (PC) | UV-resistant grade; MI 5 g/10 min (300°C/1.2 kg) | Tough, transparent engineering plastic for housings/connectors/transparent structural parts. Melt index affects flow and thin-wall molding. Selection: radiation/EtO compatibility, stress cracking, chemical resistance. | |
Medical polymer base / flexible disposables | 9002-86-2 | Polyvinyl chloride (PVC) | Low molecular weight | Common in tubing/bags/lines (often plasticized for flexibility). Research selection must consider plasticizer migration, extractables, and post-sterilization mechanical changes. Low Mw favors formulation/blend studies. | |
Medical engineering plastic / flexible copolymer | 24937-78-8 | Poly(ethylene-co-vinyl acetate) (PEVA) | 12 wt% VA; MI 8 g/10 min (190°C/2.16 kg) | EVA/PEVA: flexible and heat-sealable; used in films/tubing/adhesive layers, controlled-release matrices, and hot-melt systems. VA content determines softness and polarity. Selection: VA%, MI, additive compatibility. | |
Medical membrane material / heat-resistant polymer | 25135-51-7 | Polysulfone (PSU) | Mw ~75,000 | High heat resistance, hydrolysis resistance, dimensional stability; used in hemodialysis/filtration membranes and device parts. Suitable for casting/phase-inversion membrane studies. Selection: molecular weight, solvent system, pore structure, protein adsorption/hemocompatibility. | |
Medical engineering plastic / fluoropolymer low-friction material | 9002-84-0 | PTFE micropowder resin | Avg. particle size ~610 μm; apparent density ~490 g/L | PTFE: low friction and chemically resistant; micropowder used as lubricating/wear-resistant additive or coating filler for catheter/seal/bearing-type systems. Selection: particle size, dispersibility, matrix compatibility. | |
Medical engineering plastic / high-strength structural parts | 25038-59-9 | PET (poly(ethylene terephthalate)), 30% glass-filled | Granular; 30% glass particles as reinforcement | PET + glass fiber: high strength and dimensional stability for device structural and wear parts; glass fiber increases modulus but affects toughness and surface roughness. Selection: glass-fiber ratio, injection conditions, surface-treatment needs. | |
Characterization / QC standard | 9003-07-0 | Polypropylene melt flow rate standard | MFR 1.65 g/10 min | Standard for PP melt flow (MFR) calibration and QC; supports batch consistency, process windows, and incoming inspection in medical PP consumable development. | |
Medical tissue adhesive / cyanoacrylate | 133978-15-1 | 2-Octyl cyanoacrylate | ≥95%, stabilized with HQ | Long-chain (octyl) cyanoacrylate: yields more flexible polymer after curing; commonly used as a reference in skin-closure tissue adhesive studies and formulation comparisons. HQ is an inhibitor. Selection: polymerization rate, flexibility, wet-surface bonding. | |
Medical tissue adhesion / vascular embolization (common scaffold) | 6606-65-1 | Butyl 2-cyanoacrylate | ≥95%, stabilized with TBC | n-Butyl cyanoacrylate: fast curing and strong bonding; commonly used for rapid tissue adhesion and (e.g., NBCA-type) interventional embolization reference studies. TBC is an inhibitor. Selection: curing rate (strongly dependent on moisture/ions), working time, dilution/formulation system. |
Note: The above are representative Aladdin products. For more specifications, please refer to the product list at the end of the article or search the Aladdin website by product name/CAS.
Aladdin: https://www.aladdinsci.com/